Canaccord raises Abbvie stock price target on pipeline progress
Canaccord raised its price target on AbbVie (NYSE:ABBV) to $338 from $290, citing strong Q3 performance and pipeline progress. The stock trades near its 52-week high at $294.89. AbbVie reported Q3 revenue of $17.404B, beating estimates, and raised its 2026 guidance and dividend. Analysts highlight growth in Immunology, Neuroscience, and Oncology.
How this was made
The 30-second read
Why it matters
The guidance lift and higher price target could attract new buying interest, especially from growth‑oriented investors.
Market read
AbbVie's upgraded outlook may lift the stock and positively influence the healthcare sector.
What to watch
Potential competitive pressures and regulatory risks for new indications are not addressed.
Background
Canaccord's upgrade follows AbbVie's Q3 2026 earnings beat and a series of pipeline announcements across immunology, neuroscience, and oncology.
Ticker impact
Canaccord raised its price target on AbbVie to $338 and upgraded its earnings guidance, citing pipeline progress and Q3 results.
likely upward pressure as investors price in higher earnings and pipeline growth
The new target reflects multiple expansion and confidence in upcoming product launches, which can drive the stock higher in the near term.
Market effects
Boosts sentiment for the broader pharma/biotech sector as pipeline progress signals growth.
U.S. large‑cap healthcare index may see modest gains.
Limited to investors focused on U.S. healthcare equities.
Counterpoint
The price target may be overly optimistic if pipeline milestones are delayed.
Key entities
- companyAbbVie
U.S. pharmaceutical company (ticker ABBV).
- analyst_firmCanaccord
Equity research firm issuing the upgrade.
